Cargando…

The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China

BACKGROUND: Surgery is an important adjuvant treatment for tuberculous empyema(TE). We thus conducted a single arm-clinical retrospective study of stage II-III TE patients who underwent uniportal video-assisted thoracic surgery (Uni-VATS) over a 5-year period to evaluate the efficacy and safety of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Wenwen, Yin, Guidong, Cai, Haomin, Zhou, Yiming, Gu, Jin, Chen, Shanhao, Fan, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635196/
https://www.ncbi.nlm.nih.gov/pubmed/36329427
http://dx.doi.org/10.1186/s12890-022-02182-w
_version_ 1784824657821564928
author Sun, Wenwen
Yin, Guidong
Cai, Haomin
Zhou, Yiming
Gu, Jin
Chen, Shanhao
Fan, Lin
author_facet Sun, Wenwen
Yin, Guidong
Cai, Haomin
Zhou, Yiming
Gu, Jin
Chen, Shanhao
Fan, Lin
author_sort Sun, Wenwen
collection PubMed
description BACKGROUND: Surgery is an important adjuvant treatment for tuberculous empyema(TE). We thus conducted a single arm-clinical retrospective study of stage II-III TE patients who underwent uniportal video-assisted thoracic surgery (Uni-VATS) over a 5-year period to evaluate the efficacy and safety of surgery on TE, so as to provide the evidence for the optimal clinical strategies. METHODS: Patients diagnosed as TE with withdrawal of anti-tuberculosis-VATS were retrospectively enrolled from January 2016 to December 2021. All patients were followed up untill 12 months after withdrawal of anti-tuberculosis treatment (ATT). Clinical characteristics and surgical details were observed and analyzed to evaluate the efficacy and safety of the minimally invasive surgery. RESULTS: Totally 439 cases met included criteria were enrolled, no deaths were reported. The mean operative time was 2.6 (1.9, 4.3) hours and the mean intraoperative blood loss was 356 (240, 940) ml. Blood transfusion was performed in 20.50% (90/439) of patients and additional pneumonectomy was occurred in 9.89%(37/439)of patients .The mean postoperative drainage time was 12 (7, 49) days and the mean hospital stay was 6 (4,12) days. All stage II TE achieved complete lung re-expansion after surgery while 84.22%(315/374) of stage III achieved complete lung re-expansion, p 0.00. 15.78% (59/374) of stage III TE achieved incomplete re-expansion, 4 of which underwent a second decortication by Uni-VATS. Recurrences rate was 2.96% (13/439), including 11 cases of early recurrence and 2 cases of late recurrence at TE stage III, 5 of which underwent a second decortication by Uni-VATS. CONCLUSION: Uni-VATS is highly effective safe and minimally invasive for patients with TE, which could be recommended as the mainstream operation in areas with high TB burden.
format Online
Article
Text
id pubmed-9635196
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96351962022-11-05 The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China Sun, Wenwen Yin, Guidong Cai, Haomin Zhou, Yiming Gu, Jin Chen, Shanhao Fan, Lin BMC Pulm Med Research BACKGROUND: Surgery is an important adjuvant treatment for tuberculous empyema(TE). We thus conducted a single arm-clinical retrospective study of stage II-III TE patients who underwent uniportal video-assisted thoracic surgery (Uni-VATS) over a 5-year period to evaluate the efficacy and safety of surgery on TE, so as to provide the evidence for the optimal clinical strategies. METHODS: Patients diagnosed as TE with withdrawal of anti-tuberculosis-VATS were retrospectively enrolled from January 2016 to December 2021. All patients were followed up untill 12 months after withdrawal of anti-tuberculosis treatment (ATT). Clinical characteristics and surgical details were observed and analyzed to evaluate the efficacy and safety of the minimally invasive surgery. RESULTS: Totally 439 cases met included criteria were enrolled, no deaths were reported. The mean operative time was 2.6 (1.9, 4.3) hours and the mean intraoperative blood loss was 356 (240, 940) ml. Blood transfusion was performed in 20.50% (90/439) of patients and additional pneumonectomy was occurred in 9.89%(37/439)of patients .The mean postoperative drainage time was 12 (7, 49) days and the mean hospital stay was 6 (4,12) days. All stage II TE achieved complete lung re-expansion after surgery while 84.22%(315/374) of stage III achieved complete lung re-expansion, p 0.00. 15.78% (59/374) of stage III TE achieved incomplete re-expansion, 4 of which underwent a second decortication by Uni-VATS. Recurrences rate was 2.96% (13/439), including 11 cases of early recurrence and 2 cases of late recurrence at TE stage III, 5 of which underwent a second decortication by Uni-VATS. CONCLUSION: Uni-VATS is highly effective safe and minimally invasive for patients with TE, which could be recommended as the mainstream operation in areas with high TB burden. BioMed Central 2022-11-03 /pmc/articles/PMC9635196/ /pubmed/36329427 http://dx.doi.org/10.1186/s12890-022-02182-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Wenwen
Yin, Guidong
Cai, Haomin
Zhou, Yiming
Gu, Jin
Chen, Shanhao
Fan, Lin
The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
title The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
title_full The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
title_fullStr The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
title_full_unstemmed The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
title_short The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
title_sort efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage ii-iii tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635196/
https://www.ncbi.nlm.nih.gov/pubmed/36329427
http://dx.doi.org/10.1186/s12890-022-02182-w
work_keys_str_mv AT sunwenwen theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT yinguidong theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT caihaomin theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT zhouyiming theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT gujin theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT chenshanhao theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT fanlin theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT sunwenwen efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT yinguidong efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT caihaomin efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT zhouyiming efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT gujin efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT chenshanhao efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina
AT fanlin efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina